Fulcrum Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced the granting of non-statutory stock options to new employees as part of its 2022 Inducement Stock Incentive Plan. On August 4, 2025, Fulcrum granted an aggregate of 36,400 options to purchase shares of the company's common stock at an exercise price of $6.96 per share, consistent with the closing price of the stock on that date. Each option has a ten-year term and follows a vesting schedule over four years. The vesting begins with 25% of the shares vesting on the first anniversary of the employee's start date, followed by 6.25% of the shares vesting in equal quarterly installments over the next three years, contingent on the employee's continued service with the company. This initiative is in accordance with Nasdaq Listing Rule 5635(c)(4).